Where Will Ocugen Be in 3 Years?

Over the last three years, Ocugen's (NASDAQ: OCGN) stock has lost 60% of its value, frustrating the small biotech's early investors. But if its gains of more than 4,700% in the last 12 months are to be believed, the market is quite enthusiastic about the company's potential. This is likely thanks to its externally developed coronavirus vaccine, which might be approved for sale sometime next year.

Will its vaccine lift it to new heights by the end of 2024, or is Ocugen's time in the limelight approaching an end now that its competitors are so far ahead?

Image source: Getty Images.

Source Fool.com